Captrust Financial Advisors Has $101.39 Million Holdings in ResMed Inc. (NYSE:RMD)

Captrust Financial Advisors increased its position in ResMed Inc. (NYSE:RMD - Free Report) by 813.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 443,340 shares of the medical equipment provider's stock after purchasing an additional 394,803 shares during the period. Captrust Financial Advisors owned 0.30% of ResMed worth $101,387,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. World Investment Advisors LLC purchased a new position in shares of ResMed during the third quarter worth about $541,000. Wilmington Savings Fund Society FSB purchased a new position in shares of ResMed in the 3rd quarter valued at approximately $193,000. Franklin Resources Inc. increased its holdings in shares of ResMed by 56.5% in the third quarter. Franklin Resources Inc. now owns 174,113 shares of the medical equipment provider's stock valued at $41,909,000 after purchasing an additional 62,882 shares during the period. Principal Financial Group Inc. grew its position in ResMed by 2.9% in the 3rd quarter. Principal Financial Group Inc. now owns 186,776 shares of the medical equipment provider's stock valued at $45,596,000 after buying an additional 5,284 shares during the last quarter. Finally, Versant Capital Management Inc increased its stake in shares of ResMed by 66.3% during the fourth quarter. Versant Capital Management Inc now owns 459 shares of the medical equipment provider's stock worth $105,000 after acquiring an additional 183 shares during the period. Institutional investors and hedge funds own 54.98% of the company's stock.

Insider Activity

In related news, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $227.71, for a total value of $455,420.00. Following the transaction, the director now directly owns 75,218 shares in the company, valued at $17,127,890.78. The trade was a 2.59 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Michael J. Farrell sold 8,009 shares of ResMed stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $236.77, for a total transaction of $1,896,290.93. Following the transaction, the chief executive officer now owns 455,472 shares in the company, valued at approximately $107,842,105.44. The trade was a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 48,949 shares of company stock worth $11,283,582 over the last 90 days. 0.71% of the stock is currently owned by company insiders.

ResMed Stock Performance

Shares of NYSE:RMD traded down $1.64 during trading on Thursday, hitting $243.06. 737,793 shares of the company traded hands, compared to its average volume of 1,005,609. The stock has a market capitalization of $35.64 billion, a price-to-earnings ratio of 28.70, a PEG ratio of 1.53 and a beta of 0.78. The business's fifty day moving average is $222.89 and its 200-day moving average is $234.04. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13. ResMed Inc. has a one year low of $179.42 and a one year high of $263.05.

ResMed (NYSE:RMD - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $2.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.36 by $0.01. ResMed had a return on equity of 26.17% and a net margin of 25.34%. The business had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.28 billion. During the same period in the previous year, the firm posted $2.13 earnings per share. The business's revenue was up 7.9% on a year-over-year basis. As a group, equities analysts predict that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 12th. Shareholders of record on Thursday, May 8th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date of this dividend is Thursday, May 8th. ResMed's payout ratio is currently 23.79%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on RMD shares. The Goldman Sachs Group assumed coverage on ResMed in a report on Thursday, January 16th. They issued a "buy" rating on the stock. Piper Sandler reduced their price target on ResMed from $260.00 to $248.00 and set a "neutral" rating on the stock in a research note on Thursday, April 24th. JPMorgan Chase & Co. upped their price target on ResMed from $286.00 to $290.00 and gave the stock an "overweight" rating in a research note on Thursday, April 24th. Royal Bank of Canada raised their price objective on ResMed from $247.00 to $255.00 and gave the company a "sector perform" rating in a research report on Thursday, April 24th. Finally, KeyCorp set a $274.00 price objective on shares of ResMed in a research report on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $258.83.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.